Genentech Announces Positive Data from Broad Blood Cancer Portfolio at European Hematology Association Annual Meeting
- Long-term data at the European Hematology Association (EHA) 2022 Congress expands understanding of the impact of Genentech medicines in early-stage blood cancers with the goal of providing patients
Source: finanznachrichten.de